Abstract CT182: Camu camu plus nivolumab/ipilimumab (N/I) as first-line therapy for metastatic renal cell carcinoma (mRCC): A randomized phase I trial
Year: 2026
Type: conference-abstract
Source: Cancer Research
Authors: Regina Barragan Carrillo, Miguel Zugman, Bertrand Routy, Mallia Geiger, Xiaochen Li, Nazli Dizman, Hedyeh Ebrahimi, Salvador Jaime-Casas, Nicholas Salgia, Joann Hsu, Daniela V. Castro, Benjamin D. Mercier, Koral Sha, Sreya Duttagupta, Tanya B. Dorff, Neal S. Chawla, Ruchi Agarawal, Ekta Kapoor, Marcin Kortylewski, Alex Chehrazi-Raffle, Arielle Elkrief, Sumanta K. Pal
Institutions: Instituto Nacional de Cancerología, City Of Hope National Medical Center, Centre Hospitalier de l’Université de Montréal, The University of Texas MD Anderson Cancer Center, Beth Israel Deaconess Medical Center, Roswell Park Comprehensive Cancer Center, Sarcoma Oncology Center, University of Pennsylvania
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7154686717
Cites:
Cited by:
Related to: